Medical Insights from Industry

RSS

"Insights from Industry" is a dynamic series of interviews at the cutting edge of the medical industry. Every interviewee is a leader in their particular field and is handpicked to give an informative and accessible insight into their chosen field. These interviews are guaranteed to keep you in the know in a rapidly changing industry.

Reformulated OxyContin®: an interview with Dr. Paul Coplan, Executive Director, Risk Management and Epidemiology, Purdue Pharma

OxyContin contains oxycodone, which is an opioid agonist. It is used for the management of moderate to severe pain when a constant opioid analgesic is needed for a prolonged period of time.

29 Aug 2013

Alzheimer’s drug trial: an interview with Geoffrey Kempler, Chairman & CEO Prana Biotechnology

Approval for the IMAGINE trial was granted by the Austin Health Research Ethics Committee in November 2011, with the first patients dosed in March the following year. However, well before the trial was approved, PBT2 had already shown promise in significantly changing Abeta levels in spinal fluid while improving cognition in a previous 12-week trial conducted in 2006.

28 Aug 2013

Companion diagnostics: an interview with Trevor Hawkins, SVP, Strategy, Innovation and Business Development for Siemens Healthcare Diagnostics

Companion diagnostics is critical in helping to pave the way for personalized medicine, in which the treatment is adapted and precisely tailored to the patient.

From Siemens Healthineers 27 Aug 2013

Combating antibiotic resistance: an interview with Ron Najafi, CEO NovaBay Pharmaceuticals

Approximately 80 years ago the first antibiotic was discovered by Sir Alexander Fleming, for which he was justifiably awarded the Nobel Prize in medicine.

2 Aug 2013

Interferon-free treatment for genotype-1b hepatitis C patients: an interview with Professor Wulf Boecher, Boehringer Ingelheim

Genotype 1 is, worldwide, the most prevalent genotype of the hepatitis C virus. It accounts for around seventy percent of all hepatitis C infections.

30 Jul 2013

Artificial pancreas for type 1 diabetes patients: an interview with John Pritchard, Cambridge Consultants

Essentially, what an artificial pancreas would be doing is taking the blood glucose results from a continuous monitor and taking the data that the patient puts in about the amount she/he is eating, and then adjusting the amount of insulin being delivered by the pump based on a mathematical formula that would be very personalized to that patient.

25 Jul 2013

Fibromyalgia diagnosis: an interview with Dr. Bruce Gillis, CEO of EpicGenetics

Presently, it is a diagnosis of exclusion. Patients end up spending, according to what’s been published in the medical literature, as many as 3 - 5 years going from doctor to doctor seeking a diagnosis because they tend to have nonspecific symptoms of a subjective nature.

23 Jul 2013

Stem cells in the aesthetic industry: an interview with Dr. Norma Kassardjian

Stem Cells are special “master” cells in your body. Stem cells are the building blocks that can replicate into other kinds of cells like blood cells, heart, muscle, blood vessels and cartilage.

9 Jul 2013

p53 restoration of function drug candidate: an interview with Dr. Wayne Danter, MD, FRCPC President and CEO of Critical Outcome Technologies

COTI-2 is a computer-designed small molecule that was discovered by our artificial intelligence drug discovery platform called CHEMSAS.

8 Jul 2013

Saltwater-treatment for cystic fibrosis: an interview with Matthew Allen, Program Director at Cambridge Consultants

A group of Australian researchers, back in 2006, noted that there was a link between the severity of cystic fibrosis between sufferers who surfed, and sufferers who did not surf – and obviously Australia is a good place to spot that.

4 Jul 2013

Endoscopic imaging: an interview with Len Farris, Vice President of Marketing, Americas, PENTAX Medical

The impact of endoscopic imaging on patient care has been enormous since the first fiber optic systems were introduced more than 50 years ago. Today, high resolution and high definition systems are used to provide clinicians and patients unprecedented images from inside the body.

From PENTAX Medical Company 3 Jul 2013

Orthopedic care: an interview with Dereesa Purtell Reid, CEO of Hoag Orthopedic Institute

Similar to other surgical procedures, orthopaedic surgery continues to progress toward more minimally invasive surgical techniques, with shorter inpatient length of stays and new opportunities for some procedures to shift to the outpatient care setting.

27 Jun 2013

LDL cholesterol blood levels: an interview with Dr. Harvey Kaufman

What is LDL cholesterol? What blood level of LDL cholesterol is considered optimal and why are high levels of LDL cholesterol a key marker of death risk from heart disease? Dr. Harvey Kaufman, senior medical director of Quest Diagnostics gives us some answers.

From Quest Diagnostics 19 Jun 2013

Chemotherapy devices: an interview with Damien Salauze, head of Curie-Cancer

Although several chemotherapy treatments are now administered by the oral route (targeted chemotherapy), most chemotherapy treatments (cytotoxics) are administered by the intravenous route.

13 Jun 2013

Solid formulations of the recombinant anthrax vaccine: an interview with Dr Mark Carnegie-Brown, CEO, Glide Pharma

Anthrax vaccines have a prominent place in the history of medicine. This goes back to, Pasteur, who while everybody associates with the milk treatment process, also worked on rabies and Anthrax vaccines in cattle.

6 Jun 2013

Smartphone solutions for clinical trials

mHealth broadly refers to the use of a mobile device to send patient information to or from a medical service provider. In most medication management mobile applications that are out there now, the “information” sent is usually a unidirectional nagging reminder to the patient. The application may populate a diary or it may not.

24 May 2013

Mid-stream urine collection system: an interview with Giovanna Forte, Managing Director, Forte Medical

The mid-stream (MSU) is urine from the bladder, which carries the information clinicians need to accurately identify and diagnose a UTI, or in the case of antenatal patients, make sure all is well.

22 May 2013

Patient compliance: an interview with Dr. Bassam Damaj, CEO of Innovus Pharma

A medication’s optimal results are achieved with specific dose levels and times of administration. In order for patients to achieve the maximum benefit from a medication, they have to adhere to the prescribed dose and time of use.

20 May 2013

Ambulatory syringe pump training: an interview with Ruth Goodwin RGN, BSc Clinical Education Manager for CME Medical

Ambulatory pumps allow patients to continue receiving treatment or therapy away from a hospital, thereby leading a normal life during treatment. Due to the size and design of these pumps, patients can carry them around in a carry pouch.

17 May 2013

Peripheral neuropathic pain patch treatments: an interview with Anne Hodgkins, Astellas Pharma

Peripheral neuropathic pain is caused by lesion or disease to the peripheral somatosensory nervous system. Nerve damage that can lead to peripheral neuropathic pain can happen as a result of a range of different diseases, medications or traumatic injuries.

8 May 2013